Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-02-01
2008-09-09
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S509000
Reexamination Certificate
active
07423033
ABSTRACT:
This invention relates to novel lactams having the formula (I):to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.
REFERENCES:
patent: 4666829 (1987-05-01), Glenner et al.
patent: 5283241 (1994-02-01), Bochis et al.
patent: 5389631 (1995-02-01), Claremon
patent: 5532359 (1996-07-01), Marsters et al.
patent: 5550126 (1996-08-01), Horwell et al.
patent: 5578629 (1996-11-01), Ciccarone et al.
patent: 5593846 (1997-01-01), Schenk et al.
patent: 5595990 (1997-01-01), Baldwin et al.
patent: 5602145 (1997-02-01), Samanen
patent: 5618812 (1997-04-01), Pineiro et al.
patent: 5672596 (1997-09-01), Wyvratt et al.
patent: 5703129 (1997-12-01), Felsenstein et al.
patent: 5710153 (1998-01-01), Ohmoto et al.
patent: 5710171 (1998-01-01), Dinsmore et al.
patent: 5756528 (1998-05-01), Anthony et al.
patent: 5763437 (1998-06-01), Sato et al.
patent: 5852010 (1998-12-01), Graham et al.
patent: 5856326 (1999-01-01), Anthony et al.
patent: 5859012 (1999-01-01), Dinsmore et al.
patent: 5869682 (1999-02-01), DeSolms
patent: 5872135 (1999-02-01), DeSolms
patent: 5885995 (1999-03-01), Dinsmore
patent: 5891889 (1999-04-01), Anthony et al.
patent: 5905077 (1999-05-01), Jungheim et al.
patent: 5919785 (1999-07-01), Dinsmore et al.
patent: 5936089 (1999-08-01), Carpino et al.
patent: 5965578 (1999-10-01), Graham et al.
patent: 6503902 (2003-01-01), Olson et al.
patent: 2003/0166636 (2003-09-01), Olson et al.
patent: 2934355 (1981-03-01), None
patent: 0421802 (1991-04-01), None
patent: 0434360 (1991-06-01), None
patent: 0652009 (1995-05-01), None
patent: 0842944 (1998-05-01), None
patent: WO 9403437 (1994-02-01), None
patent: WO 9405634 (1994-03-01), None
patent: WO 9414776 (1994-07-01), None
patent: WO 9509633 (1995-04-01), None
patent: WO 9617833 (1996-06-01), None
patent: WO 9618602 (1996-06-01), None
patent: WO 9620918 (1996-07-01), None
patent: WO 9633165 (1996-10-01), None
patent: WO 9639137 (1996-12-01), None
patent: WO 9719053 (1997-05-01), None
patent: WO 9727852 (1997-08-01), None
patent: WO 9736877 (1997-10-01), None
patent: WO 9736879 (1997-10-01), None
patent: WO 9736900 (1997-10-01), None
patent: WO 9738664 (1997-10-01), None
patent: WO 9745412 (1997-12-01), None
patent: WO 9816523 (1998-04-01), None
patent: WO 9822430 (1998-05-01), None
patent: WO 9822433 (1998-05-01), None
patent: WO 9822441 (1998-05-01), None
patent: WO 9822493 (1998-05-01), None
patent: WO 9827053 (1998-06-01), None
patent: WO 9828268 (1998-07-01), None
patent: WO 9828980 (1998-07-01), None
patent: WO 9837079 (1998-08-01), None
patent: WO 9841510 (1998-09-01), None
patent: WO 9844797 (1998-10-01), None
patent: WO 9858915 (1998-12-01), None
patent: WO 9900654 (1999-01-01), None
patent: WO 9903826 (1999-01-01), None
patent: WO 9907730 (1999-02-01), None
patent: WO 9907731 (1999-02-01), None
patent: WO 9917777 (1999-04-01), None
patent: WO 9918951 (1999-04-01), None
patent: WO 9919305 (1999-04-01), None
patent: WO 9932453 (1999-07-01), None
patent: WO 9966934 (1999-12-01), None
patent: WO 9967219 (1999-12-01), None
patent: WO 9967220 (1999-12-01), None
patent: WO 9967221 (1999-12-01), None
patent: WO 0007995 (2000-02-01), None
patent: WO 0038618 (2000-07-01), None
patent: WO 0119797 (2001-03-01), None
U.S. Appl. No. 09/661,008, filed Sep. 13, 2000, Olson et al.
U.S. Appl. No. 60/153,511, filed Sep. 13 1999, Olson et al.
U.S. Appl. No. 60/224,388, filed Aug. 9, 2000, Olson et al.
H. C. Ardnt,Synthesis 1979, pp. 202-204.
M.-C. Bettembourg et al.,Bull. Soc. Chim. Fr. 1963, pp. 2449-2451.
Bock et al.,J. Med. Chem., 1989, 32, pp. 13-16.
Bock et al.,J. Org. Chem 1987, 52, pp. 3232-3239.
M. Braun,Synthesis 1989, p. 856.
Brown et al.,Tetrahedron Letters, 1971, 8, pp. 667-670.
Castro et al.,J. Med. Chem., 1997, 40, pp. 2491-2501.
M. S. Chambers et al.,Bioorg.&Med. Chem. Lett., 1993, 3 (10), pp. 1919-1924.
A. R. Chamberlin,Chem. Rev. 1997, 97, pp. 2243-2266.
T. Cohen et al.,J. Org. Chem. 1995, 60, p. 2022.
M. T. Crimmins et al.,J. Am. Chem Soc. 1997, 119, pp. 7883-7884.
S.G. Davis et al.,Synlett 1995, p. 700.
D. A. Evans,J. Org. Chem. 1993, 58, pp. 2446-2453.
D. A. Evans et al.,Org. Synth 1990, 68, p. 83-90.
D. A. Evans et al.,Tetrahedron Lett. 1994, 35 (39), pp. 7171-7172.
A. Furstner et al.,J. Org. Chem. 1994, 59 (18), pp. 5215-5229.
A. Furstner et al. Tetrahedron 1995,51(3) pp. 773-786.
Glenner and Wong,Biochem. Biophys. Res. Commun.120; pp. 885-890 (1984).
A. K. Ghosh,J. Am. Chem. Soc. 1996, 118, pp. 2527-2528.
J. H. Gogerty et al.,J. Med. Chem., 1977, 20 (7), p. 952.
T. Imamoto et al. J.Org.Chem. 1984,49,pp. 3904-3912.
J. Jurczak et al.,Synlett 1993, p. 241.
T.CohenJ. Org. Chem. 1992, 57, p. 6.
T. Imamoto.J. Am. Chem. Soc. 1989,111 pp. 4392-4398.
L.Kruse et al.J.Med.Chem. 1987, 30 ,pp. 486-494.
A. S. Kende et al.,Tetrahedron Lett. 1989, 30 (43), 5821-5824.
P. Kocienski,Tetrahedron 1990, 46, pp. 1767-1782.
R. C. Larock, “Comprehensive Organic Transformations,”Wiley-VCH : 1989, pp. 604-614 and 963-964.
S. V. Ley et al.,Synthesis 1994, p. 639.
S. Masamune et al.,J. Am. Chem. Soc. 1997, 119, p. 2586.
T. Mukaiyama et al.,Org. React. 1994, pp. 1-104.
H. Mulzer et al.,Tetrahedron Lett. 1995, 36 (42), pp. 7643-7646.
S. Nozaki et al.,Bull. Chem. Soc. Jpn. 1982, 55, pp. 2165-2168.
M.HudlickyOxidation in Organic Chemistry, ACS, 1990, pp. 250-264.
M. W. Partridge et al.,J. Chem. Soc. 1964, p. 3673.
I. Paterson et al.,Org. React. 1997, 51, pp. 1-200.
G. R. Pettit,Synthesis 1996, pp. 719-725.
T. Cohen.Phosphorus, Sulfur, and Silicon 1993, 74, p. 1.
“Remington's Pharmeceutical Sciences,”17th ed. Mack Publishing Company, Easton, PA, 1985, p. 1418.
D. J. Selkoe, “Cell Biology of the amyloid (beta)-protein precursor and the mechanism of Alzheimer's disease,”Annu. Rev. Cell. Biol.1994, 10: pp. 373-403.
G. Semple et al.,Bioorg.&Med. Chem. Lett., 1996, 6(1), pp. 51-58.
G. Semple et al.,J. Med. Chem., 1997, 40, pp. 331-341.
G. Semple et al., Synth.Commun. 1996,26 (4),pp. 721-727.
R.G. Sherrill et al.,J. Org. Chem. 1995, 60, pp. 730-734.
G. A. Showell et al.,J. Med. Chem., 1994, 37, pp. 719-721.
D. Swern,Synthesis 1981, pp. 165-185.
T.CohenTetrahedron 1994, 50, pp. 11569-11584 and 12793-12810.
D. A. Walsh,Synthesis, Sep. 1980, p. 677.
M.C. Marcotullio J.Org Chem 1994, 59, pp. 2884.
D.A. Evans. Aldrichimica Acta 1982,15pp. 23-32.
M.Yoon et al. J.Org.Chem.1985, 50, pp. 2443-2450.
S. M. Weinreb,Tetrahedron Lett. 1981, 22, pp. 3815-3818.
Dingwall; J. Clinical Invest., 108, Nov. 2001, 1243-1246.
Selkoe; J. Alzheimer's Disease, 3, 2001, p. 75-81.
Tanzi and Parson, “Decoding Darkness, The Search for the Genetic Causes of Alzheimer's Disease”, Perseus Publishing, 2000, pp. xvii-xviii.
Olson et al., Current Opinion in Drug Discovery and Development, 4, 2001, p. 390-401.
P. J. Maurer et al, “Total synthesis of a mycobactin; mycobactin S2” Journal of the American Chemical Society, vol. 105, No. 2, 1983, pp. 240-245.
M. Adamczeski et al, Novel sponge-derived amino acids, Journal of the American Chemical Society, Vo. 111, No. 2, 1989, pp. 647-654.
International Search Report PCT/US00/24967 dated Jul. 24, 2001.
Liu Hong
Olson Richard E.
Thompson Lorin Andrew
Bristol-Myers Squibb Pharma Company
Kelly Drye & Warren LLP
Kifle Bruck
Mingo Pamela A.
LandOfFree
Hydroxyalkanoylaminolactams and related structures as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydroxyalkanoylaminolactams and related structures as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxyalkanoylaminolactams and related structures as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3977037